Form 4: Artiva Biotherapeutics CEO Fred Aslan Reports Changes in Beneficial Ownership
SEC Filing
Fred Aslan, CEO of Artiva Biotherapeutics, reports acquisition and disposal of common stock and adjustment of restricted stock units.
Summary
- Fred Aslan, the President and CEO of Artiva Biotherapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
- On March 5, 2025, Aslan acquired 200,000 shares of common stock.
- These shares were acquired through a restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
- The filing also reflects a reduction in the number of shares subject to a previously granted RSU on July 22, 2024, from 228,905 shares to 216,665 shares.
- This adjustment was due to the partial exercise of the underwriters' option to purchase additional shares in connection with the company's IPO.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report changes in their ownership of company stock, ensuring transparency and compliance with SEC regulations.
Key Dates
| Date | Description |
|---|---|
| July 22, 2024 | Date of original RSU grant that was later adjusted. |
| March 05, 2025 | Date of common stock acquisition and RSU adjustment. |
| March 07, 2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.